{"changeSha256":"4bebb2b63063744366e4746d7ca76ccd2c420ff0d3dafdafab63bdf4eac00671","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.","before":"An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.","field":"Profile summary"},{"after":"Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.","before":"ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.","field":"Evidence note"},{"after":"Zenagamtide","before":"None recorded","field":"Related names"},{"after":"ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080","before":"ctg-nct06049329-v6","field":"Cited source records"},{"after":"name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080","before":"name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6; summary: ctg-nct06049329-v6; evidenceNote: ctg-nct06049329-v6","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/amycretin/versions/3/","version":3},"id":"profile:amycretin:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, published trial results from our human evidence review, and the 2026 report that renames amycretin zenagamtide.","peptideSlugs":["amycretin"],"previousChangeEvent":{"path":"/corrections/v1/profiles/amycretin/v2.json","sha256":"0f5f25f50c9ad5e6def6715abfe0f4e0d7842f59cb25c42d91f87e199978dab1"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/amycretin/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-40550229","name":"The Lancet","sourceClass":"A","title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (2025) · PMID 40550229","url":"https://doi.org/10.1016/S0140-6736(25)01176-6","verifiedAt":"2026-11-14"},{"id":"journal-pmid-42532080","name":"The Lancet","sourceClass":"A","title":"Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080","url":"https://doi.org/10.1016/S0140-6736(26)01248-1","verifiedAt":"2026-11-14"}],"subject":{"slug":"amycretin","type":"profile"}}
